TY - JOUR T1 - SARS-Cov-2 proliferation: an analytical aggregate-level model JF - medRxiv DO - 10.1101/2020.08.20.20178301 SP - 2020.08.20.20178301 AU - Thomas Pitschel Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/18/2020.08.20.20178301.abstract N2 - An intuitive mathematical model describing the virus proliferation is presented and its parameters estimated from time series of observed reported CoViD-19 cases in Germany. The model replicates the main essential characteristics of the proliferation in a stylized form, and thus can support the systematic reasoning about interventional measures (or their lifting) that were discussed during summer and which currently become relevant again in some countries. The model differs in form from elementary SIR models, but is contained in the general Kermack-McKendrick (1927) model. It is maintained that (compared to elementary SIR models) the model is more faithfully representing real proliferation at the instantaneous level, leading to overall more plausible association of model parameters to physical transmission and recovery parameters. The main policy-oriented results are that (1) mitigation measures imposed in March 2020 in Germany were absolutely necessary to avoid health care resource exhaustion, (2) fast response is key to containment in case of renewed outbreaks. Two model generalizations aiming to better represent the true infectiousness profile and aiming to incorporate recurring susceptibility are stated and numerical results for the latter are presented.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval required; no personal human data included.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw input data used have been obtained from Robert-Koch-Institut, Berlin. (see link) An alternative source for the same data is the European Centre for Disease Prevention and Control. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.html https://data.europa.eu/euodp/en/data/dataset/covid-19-coronavirus-data ER -